摘要
采用乳化聚合法制备黄藤素纳米粒(F-PBCA-NP),以形态、粒径、载药量和包封率为考察指标,通过L9(34)正交设计优化制备工艺;同时以金黄色葡萄球菌感染的小鼠为实验动物,用小鼠的存活率和重要脏器的重量指数变化为评判指标,对其抗感染作用进行观察,并与非纳米化的普通制剂对比。结果表明,黄藤素纳米粒为均匀圆整的类球形实体粒子,平均粒径64 nm,载药量50.9%,包封率67.8%;黄藤素纳米粒可使感染金黄色葡萄球菌小鼠的存活率达到80%,而普通制剂为35%,减轻脾脏重量指数比普通制剂显著提高。故该制备工艺稳定可靠,所制黄藤素纳米粒的抑菌效果比片剂和胶囊显著增强。
The emulsion polymerization was used to manufacture PBCA-NP loaded with Fibrauretin.The process was optimized by L9（34） orthogonal design test with morphology,particle size,drug loading and embedding ratio of nanoparticles as the standard;at the same time,the anti-infection effect was viewed in mice infected with S.aureas as the experimental animals,the survival rates of mice,weight indexes of important organs served as judgement standard compared with other preparations.The results indicated that the morphology of F-PBCA-NP was sphere,the diameter was 64nm,the drug loading was 50.9%,the embedding ratio was 67.8%;the antibacterial action of the F-PBCA-NP was increased,compared with others,in the survival rate of mice infected with S.aureas was 80% in F-PBCA-NP group,but 35% in the ordinary preparations,had more improvements on spleen weight index than others.It is concluded that the preparation method of F-PBCA-NP is stable and feasible,which showed the antibacterial action of the fibrauretin nanoparticles is better than that of the tablet and capsule.
出处
《动物医学进展》
CSCD
北大核心
2010年第4期38-42,共5页
Progress In Veterinary Medicine
